Skip to main content

Table 2 Selected agents investigated in the management of GIST

From: Extra-gastrointestinal stromal tumor of the pancreas: case report and review of the literature

Author Year Pts (n) Phase study Treatment End point Outcome (% or median) P value
Demetri et al. [42] 2002 147 II Imatinib OR 81.6%  
Demetri GD et al. [43] 2006 312 III Sunitinib/placebo TTP 27.3 vs. 5.4 weeks <0.0001
Blanke et al. [44] 2008 746 III Imatinib 400 mg/ PFS 18 vs. 20 months 0.13
Imatinib 800 mg OS 55 vs. 51 months 0.83
De Matteo et al. [45] 2009 713 III Imatinib/placebo PFS 98% vs. 83% <0.0001
Dubreuil et al. [46] 2009 30 II Masitinib PFS 165.2 weeks  
Sawaki et al. [47] 2011 35 II Nilotinib PFS 16 weeks  
Park et al. [48] 2011 31 II Sorafenib PFS 4.9 months  
OS 9.7 months
Joensuu et al. [49] 2012 400 III Imatinib 12mo/36mo RFS & OS 65.6% vs. 47.9% <0.0001
       92.0% vs. 81.7% 0.019
  1. OR = overall response; OS = overall survival; PFS = progression-free survival; RFS = recurrence-free survival; TTP = time to tumor progression.